The safest way to lower hematocrit on TRT is to reduce testosterone peaks by lowering the dose and/or switching from infrequent injections to more frequent micro-dosing or a steadier transdermal method, because testosterone increases red blood cell production through kidney-driven erythropoietin (EPO) signaling. Since elevated hematocrit affects roughly 5% to 66% of men on therapy, the goal is to fix the “spiky” protocol causing overproduction rather than reflexively stopping TRT.

“We often see men panic when their hematocrit climbs, fearing they must stop therapy immediately. In reality, this is usually a mechanical issue of dosage and delivery method. We don’t just want to bleed you; we want to adjust the protocol so your body stops overproducing red cells in the first place.”

Susan Carter, MD, Endocrinologist & Longevity expert

Key takeaways

Lower hematocrit on TRT by reducing testosterone peaks. Common levers include lowering the dose, splitting injections into smaller, more frequent doses, switching to subcutaneous injections, or using a steadier transdermal option.
TRT-related hematocrit rises mainly via increased kidney EPO signaling and reduced hepcidin, which increases iron availability for red blood cell production.
Elevated hematocrit is the most common dose-limiting TRT side effect (reported roughly 5% to 66%). Risk is higher with injectable esters and infrequent dosing schedules that create higher peaks.
Many clinicians take action around hematocrit ~52% to 54% (threshold varies). Typical steps include holding or adjusting TRT and addressing contributing causes, with clinician-directed phlebotomy considered when appropriate.
Blood donation or therapeutic phlebotomy can lower hematocrit quickly, but iron stores (ferritin) should be monitored and the schedule individualized by a clinician.

The relationship

Testosterone replacement therapy (TRT) is a powerful tool for men dealing with hypogonadism, helping to restore muscle mass, libido, and cognitive function. However, the same biological mechanisms that revitalize your energy can also drive your bone marrow into overdrive. This results in secondary erythrocytosis, a condition where the body produces too many red blood cells.

The primary marker for this condition is hematocrit. Hematocrit measures the volume percentage of red blood cells in your blood. When you introduce exogenous testosterone (testosterone that comes from outside your body), you significantly alter the hormonal signals sent to your kidneys and bone marrow. Research indicates that anywhere from 5 percent to 66 percent of men on TRT will experience elevated hematocrit, making it the most common dose-limiting side effect of therapy.

This relationship is dose-dependent and formulation-dependent. Men using injectable testosterone esters, particularly those on less frequent dosing schedules (like once every two weeks), experience higher peaks in serum testosterone. These sharp peaks signal the body to produce red blood cells more aggressively than steady-state methods like transdermal gels or creams. Understanding how to lower hematocrit on TRT often begins with understanding that your current protocol might be too “spiky” for your physiology.

How it works

The EPO pathway

The primary driver of high hematocrit in men on TRT is erythropoietin (EPO). EPO is a hormone produced by the kidneys that signals the bone marrow to produce red blood cells. Testosterone stimulates the kidneys to secrete more EPO, directly increasing red blood cell production.^[1] According to a 2014 study in The Journals of Gerontology: Series A, testosterone-induced erythrocytosis tracks with increased EPO and a shift in the body’s hemoglobin set point.^[1] This is a natural function of male biology; androgens naturally drive higher hemoglobin and hematocrit levels. However, when you inject testosterone, you may elevate levels beyond your physiological baseline, causing an exaggerated EPO response.

Hepcidin suppression

A less discussed but critical mechanism involves hepcidin, a key regulator of iron metabolism. Hepcidin is a peptide hormone produced by the liver that controls how much iron your body absorbs from food and releases from storage.

Testosterone suppresses hepcidin levels.^[2] When hepcidin is low, your body absorbs iron more efficiently from your diet and unlocks stored iron for use. Since iron is a primary building block of red blood cells, this increased availability removes the “brakes” on red blood cell production. The combination of high EPO (stepping on the gas) and low hepcidin (releasing the parking brake) creates the perfect storm for rapid erythrocytosis.

Estradiol conversion

Some testosterone converts to estradiol through a process called aromatization. While the evidence is mixed, some data suggests that estradiol may potentiate the effects of EPO or directly influence stem cells in the bone marrow. Men with higher body fat percentages often convert more testosterone to estradiol, potentially compounding the risk of high hematocrit, although this is secondary to the direct androgen effect.

Meta analyses indicate that symptomatic men with total testosterone below 350 ng/dL (≈12 nmol/L) are most likely to benefit from TRT. If total testosterone is borderline, measure free testosterone; values below 100 pg/mL (≈10 ng/dL) support hypogonadism. In practice, use 350 ng/dL for total or 100 pg/mL for free as decision thresholds when symptoms persist. When treating to these levels, managing the delicate balance of red blood cell production becomes critical.

Conditions linked to it

The primary clinical concern with high hematocrit is hyperviscosity (the thickening of the blood). As blood becomes more viscous, blood flow resistance increases, forcing the heart to pump harder and potentially slowing the transit of oxygen through the smallest blood vessels (capillaries).

If left unmanaged, TRT-induced polycythemia is associated with an increased risk of venous thromboembolism (VTE). VTE includes deep vein thrombosis (DVT), a clot in the deep veins of the leg, and pulmonary embolism (PE), where a clot breaks loose and travels to the lungs.^[3] A 2016 BMJ population-based case-control study reported an association between testosterone treatment and VTE risk, particularly around treatment initiation.^[3] The risk is particularly relevant during the first year of treatment when hematocrit levels tend to rise most sharply.

There is also a link to hypertension (high blood pressure) and potential cardiovascular events like myocardial infarction (heart attack) and stroke. However, it is important to note a limitation in the data: secondary erythrocytosis (caused by TRT) may not carry the exact same immediate risk profile as primary polycythemia vera (a bone marrow cancer). According to the 2018 American Urological Association guideline on testosterone deficiency, clinicians should monitor hematocrit and address TRT-associated elevations as clinically significant regardless of the origin.^[4]

Symptoms and signals

Many men with elevated hematocrit are asymptomatic, meaning they feel fine even as their numbers climb into the danger zone. This is why routine blood work is non-negotiable. However, when symptoms do appear, they are often distinct.

Facial flushing: A persistent redness in the face, neck, or ears, often looking like a mild sunburn that won’t go away.
High blood pressure: Unexplained increases in systolic or diastolic pressure despite no changes in diet or stress.
Headaches: A dull, throbbing sensation or a feeling of “fullness” in the head.
Blurry vision: Transient visual disturbances caused by sluggish blood flow in the retinal vessels.
Fatigue: Paradoxically, while red blood cells carry oxygen, blood that is too thick moves so slowly that oxygen delivery becomes inefficient, leading to tiredness.
Itching (Pruritus): Specifically after a warm shower or bath, known as aquagenic pruritus.
Night sweats: Excessive sweating during sleep that is not related to room temperature.

Seek urgent medical care if you have symptoms that could indicate a clot or stroke, such as chest pain, shortness of breath, coughing blood, one-sided leg swelling or pain, sudden weakness or numbness, or trouble speaking. Also remember that symptoms and lab values do not always match. A mild hematocrit elevation can be dangerous in some men with risk factors (for example, clot history or severe sleep apnea), while others feel symptomatic mainly from iron depletion after phlebotomy. If a result is unexpected, repeat labs when you are well-hydrated and not acutely ill, and discuss the trend (not a single number) with your clinician.

What to do about it

If your lab work shows a hematocrit level above 52% or 54% (depending on your urologist’s threshold), you need an actionable plan. Do not ignore it, but do not panic. Here is the evidence-based approach to lowering hematocrit while maintaining the benefits of therapy.

Switch to subcutaneous or transdermal administration: The pharmacokinetics (how the drug moves through your body) matter immensely. Intramuscular injections (IM) create high supraphysiological peaks of testosterone shortly after the shot. These peaks can trigger EPO release aggressively. Shifting to subcutaneous injections (small needles into belly fat) leads to slower absorption and lower peaks, often mitigating the hematocrit rise.
Alternatively, switching to transdermal gels or creams mimics the body’s natural diurnal rhythm and avoids the massive spikes associated with injections. Studies consistently show that transdermal testosterone is associated with a significantly lower risk of erythrocytosis compared to injectable formulations.^[5]
Therapeutic phlebotomy (Blood donation): This is the most immediate way to lower hematocrit. Phlebotomy involves removing approximately one pint of blood, which reduces circulating red cell mass. The timing and frequency should be clinician-directed and individualized based on hematocrit and hemoglobin trends, symptoms, comorbidities (such as cardiovascular disease or sleep apnea), and iron stores (ferritin). Some men are not eligible to donate through standard blood centers and may need therapeutic phlebotomy ordered by a clinician.
However, this is a double-edged sword. Frequent phlebotomy can deplete ferritin (stored iron). If ferritin drops too low, you may experience fatigue, restless legs, and brain fog. These symptoms can mimic low testosterone. Monitor ferritin alongside hematocrit. If ferritin is low (often under 30 to 50 ng/mL, depending on the lab and clinical context) but hematocrit is still high, donating again may worsen iron deficiency. In that scenario, TRT dose and delivery adjustments, plus evaluation of contributing conditions, become the safer path.
Address sleep apnea: This is the most overlooked factor. Obstructive sleep apnea (OSA) causes oxygen levels to drop at night. In response to hypoxia (low oxygen), kidneys increase EPO to produce more red blood cells. TRT can worsen untreated sleep apnea. If you snore, have witnessed apneas, or wake up unrefreshed, get a sleep study. Treating apnea with CPAP can reduce the drive toward erythrocytosis and may lower hematocrit without major TRT changes.^[6]

Myth vs Fact: Managing Thick Blood

Myth: Drinking more water will permanently fix high hematocrit.

Fact: Hydration only helps temporarily. Dehydration concentrates your blood, giving a falsely high reading on a lab test. Rehydrating can normalize the test result, but it does not stop your bone marrow from overproducing cells.
Myth: Taking aspirin lowers hematocrit.

Fact: Aspirin does not lower red blood cell count. It is an anti-platelet agent that reduces platelet aggregation. It may reduce clot risk in selected patients, but it does not change hematocrit.
Myth: You should stop TRT immediately if you hit 54%.

Fact: Do not stop abruptly unless a clinician directs you to do so for an emergency. Stopping can cause a hormonal crash. Often, the approach is to hold or reduce the dose, address drivers like OSA or dehydration, consider clinician-directed phlebotomy when appropriate, and then restart at a lower dose or different frequency.
Myth: Eating grapefruit helps lower hematocrit.

Fact: There is limited evidence that naringin (in grapefruit) may increase red blood cell breakdown, but the effect is small and unpredictable. Grapefruit also interferes with many medications. Do not rely on produce to manage clinical side effects.

Bottom line

The safest ways to lower hematocrit on TRT are to reduce testosterone peaks (dose reduction, more frequent dosing, or switching formulation), and to evaluate and treat contributors like obstructive sleep apnea. If hematocrit remains high or symptoms suggest hyperviscosity, clinician-directed blood donation or therapeutic phlebotomy may be used, with ferritin monitoring to avoid iron deficiency.

References

Bachman E, Travison TG, Basaria S, et al. Testosterone induces erythrocytosis via increased erythropoietin and suppressed hepcidin: evidence for a new erythropoietin/hemoglobin set point. The journals of gerontology. Series A, Biological sciences and medical sciences. 2014;69:725-35. PMID: 24158761
Guo W, Bachman E, Li M, et al. Testosterone administration inhibits hepcidin transcription and is associated with increased iron incorporation into red blood cells. Aging cell. 2013;12:280-91. PMID: 23399021
Martinez C, Suissa S, Rietbrock S, et al. Testosterone treatment and risk of venous thromboembolism: population based case-control study. BMJ (Clinical research ed.). 2016;355:i5968. PMID: 27903495
Mulhall JP, Trost LW, Brannigan RE, et al. Evaluation and Management of Testosterone Deficiency: AUA Guideline. The Journal of urology. 2018;200:423-432. PMID: 29601923
Ohlander SJ, Varghese B, Pastuszak AW. Erythrocytosis Following Testosterone Therapy. Sexual medicine reviews. 2018;6:77-85. PMID: 28526632
Killick R, Wang D, Hoyos CM, et al. The effects of testosterone on ventilatory responses in men with obstructive sleep apnea: a randomised, placebo-controlled trial. Journal of sleep research. 2013;22:331-6. PMID: 23331844

How to lower hematocrit on trt safely and effectively

Key takeaways

The relationship